Several effective anti-inflammatory agents and bronchodilators are available for controlling patients’ mild or moderate asthma. However, despite the market entry of LAMAs (e.g., Boehringer Ingelheim’s Spiriva) and novel biologics (e.g., AstraZeneca’s Fasenra, Sanofi/Regeneron’s Dupixent), an unmet need remains for effective therapies for severe disease, especially for patients whose symptoms are not adequately controlled with current therapies or who depend on frequent SABA or oral corticosteroid use to achieve relief. This Unmet Need report provides quantitative insight into key treatment drivers and goals and the current level of unmet need in severe asthma based on the perceptions of U.S. and European physicians. We analyze the commercial opportunities and how emerging therapies could capitalize on these opportunities.
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany.
Primary research: Survey of approximately 30 U.S. pulmonologists, 30 U.S. allergists, and 30 European pulmonologists.
Key companies: Roche, Novartis, GlaxoSmithKline, Teva, AstraZeneca, Regeneron, Sanofi, Boehringer Ingelheim.
Key drugs: Xolair, Nucala, Cinqair/Cinqaero, Fasenra, Dupixent, Spiriva (tiotropium).